Inhaled sildenafil nanocomposites: lung accumulation and pulmonary pharmacokinetics^*

Abstract

Context: Administration of sildenafil citrate (SC) is considered as a strategy in the treatment of pulmonary hypertension.

Objective: This study reports production of the inhalable microparticles containing SC-loaded poly(lactide-co-glycolic acid)-nanoparticles.

Methods: SC-nanoparticles were prepared by the double emulsion solvent evaporation method. Next, free SC and SC-loaded nanoparticles were spray dried in the presence of appropriate excipients (lactose, maltose and trehalose). Physicochemical properties and aerodynamic behavior of prepared powders were evaluated. In addition, drug accumulation from selected formulations in the rat lung tissue was compared with oral and IV administration.

Results: Size and fine particle fraction of selected nanocomposites and free SC microparticles were 7 and 4.5 µm, and 60.2% and 68.2%, respectively. Following oral and IV administration, the drug was not detectable in the lung after 4 and 6 h, respectively, but in SC-loaded nanoparticles, the drug was detectable in the lung even after 12 h of inhalation. Respirable particles containing free SC provided high concentration at first that was detectable up to 6 after insufflation.

Conclusion: In vivo study demonstrated that pulmonary administration of sildenafil and sildenafil nanoparticles produced longer half-life and higher concentration of the drug in the lung tissue as compared to oral and IV administration. So, these formulations could be more effective than oral and IV administration of this drug.

• Controlled release
• in vivo
• nanoparticles
• pulmonary delivery
• sildenafil citrate

Declaration of interest

This work was supported by the Tehran University of Medical Sciences. All authors have contributed significantly to the research and preparation, design and final production of the manuscript and approve its submission.

Notes

* This study was a PhD thesis of the first author.